Asian-variant intravascular lymphoma in the African race

Holly Geyer, Nina Karin, Brian Palen, Ruben Mesa
Division of Hematology - Oncology, Mayo Clinic, Scottsdale, AZ, USA

Abstract

Intravascular Large B-cell lymphoma (IVLBCL) is an exceptionally rare form of non-Hodgkin lymphoma (NHL) distinguished by the preferential growth of neoplastic cells within blood vessel lumens. CHallenging to detect and deemed disseminated at diagnosis, this condition is characterized by a highly aggressive, inconspicuous course with a high mortality rate. We describe the case of a 48 year-old African-American female presenting with a two-month history of low-grade fevers and malaise. Laboratory data was notable for anemia, thrombocytopenia, elevated liver function tests, and hematuria. An extensive work-up for infectious, rheumatologic and malignant causes was negative. Her symptoms progressed within two weeks, she was admitted for disseminated intravascular coagulation (DIC). Her course was complicated by diffuse pulmonary hemorrhage and ultimately, care was withdrawn. Autopsy identified widespread CD-20 positive intravascular large B-cell lymphoma with significant hepatosplenic involvement, characteristic of the Asian variant IVLBCL. This case uniquely highlights development of the Asian variant IVLBCL in an African-American woman with no resolution of symptoms. She was subsequently admitted for further work-up. On admission, her laboratory data was notable for anemia and thrombocytopenia. Initial testing included a bronchoalveolar lavage (BAL) and lumbar puncture, which were non-diagnostic. A liver biopsy was notable for a mononuclear infiltrate consistent with chronic hepatitis. Laboratory data was notable for a normal Coombs test, autoimmune and vasculitic panel, and hepatitis panel. Computed tomography of the chest, abdomen and pelvis (CT-CAP) was unremarkable. She was discharged one month later with no formal diagnosis.

Within two weeks, she was re-admitted for progression of symptoms. Admission laboratory data was notable for severe anemia (Hgb 6.0 g/dL), leukopenia (2.5 g/dL); thrombocytopenia (10×10^9), and an elevated lactate dehydrogenase (LDH; 1900 U/L; reference range 122-222 U/L). Aspartate transaminase (AST; 77 U/L), alanine aminotransferase (ALT; 46 U/L), total bilirubin (8.8 mg/dL) and direct bilirubin (6.2 mg/dL) were all noted to be elevated. Haptoglobin was low. Prothrombin time (PT), activated partial thromboplastin time (APTT) and d-dimer levels were elevated. A peripheral blood smear showed schistocytes and polychromasia. Findings were deemed consistent with microangiopathic hemolytic anemia and disseminated intravascular coagulation (DIC). She was treated with plasma exchange and high dose steroid administration (methylprednisolone 125 mg/day) without effect. An extensive work-up for viral, bacterial and fungal pathogens was again, non-revealing. Magnetic resonance cholangiopancreatography (MRCP) of the liver showed hepatosplenomegaly with intra-organ hemosiderin deposition. Repeat CT-CAP defined diffuse hazy opacities in both lungs, hepatosplenomegaly and mild thickening of the walls of the cecum and ascending colon (Figure 1). On repeat CT of the chest three days later, there was interval increase in the bilateral nodular opacities, air bronchograms, subcutaneous anasarca and findings consistent with pulmonary edema (Figure 2). Bronchoalveolar lavage (BAL) identified diffuse pulmonary hemorrhages. On hospital day 5, the patient rapidly developed acute respiratory distress syndrome (ARDS) and pulseless electrical activity (PEA). Despite successful resuscitation, she remained unresponsive and care was ultimately withdrawn.

Bone marrow biopsy results performed earlier that week were available following her demise. Samples showed evidence of hypercellular (80-90% cellular) with trilineage hematopoiesis and a subtle atypical mononuclear cell infiltrate composed of large cells with slightly irregular nuclear contours and multiple visible nucleoli. An autopsy identified diffuse alveolar hemorrhage, bilateral renal congestion with acute tubular necrosis (ATN), hepatomegaly and a single enlarged perisplenic lymph node. Histological examination of multiple organs confirmed diffuse intravascular large B-cell type lymphoma (IVLBCL).

Histologic and immunohistochemical findings

Histological examination showed capillary wall congestion with large atypical lymphocytes (Figure 3). On higher magnification, lymphocytes displayed vesicular nuclei, prominent nucleoli and frequent mitotic figures (Figure 4). Some cells showed coarse nuclear chromatin or irregular and indented nuclei (Figure 4). Staining with common leukocyte antigen and B cell marker CD-20 exhibited strong uptake by neoplastic cells (Figure 5).

Discussion

First characterized by Pfleger and Tappeiner in 1959, IVLBCL has emerged as an elusive malignancy characterized by a covert presentation and highly aggressive course. It is defined by the World Health Organization (WHO) as a rare and highly aggressive lymphoma variant, identified by the proliferation of large tumor cells within the lumen of small to mediumsized vessels.1 We present the first reported case of the Asian variant IVLBCL in an African-American individual and proceed to review its unique presentation, progression and response to treatment.

Since its first description more than half-a-century ago, literature on IVLBCL has continued to accumulate. Until recently, the relative paucity of cases has limited epidemiologic
research. However, it is currently recognized as a disease primarily of the elderly, with a median age in the sixth decade of life and a male-to-female ratio exceeding 3:1. The wide variability in IVLBCL's clinical presentation makes detection challenging with the majority of patients present late within the disease process. Despite variability in presentation, specific patterns have been successfully traced to a surprising common entity: the geographic distribution of patients. Appropriately reflecting their origins, two main subtypes IVLBCL are recognized: the western variant and the Asian variant. The western or classical variant remains the most common sub-type identified in North America and Europe. It is characterized by a prominence of neurologic and dermatologic findings, both at initial presentation and throughout its course. Neurologic symptoms may include alterations in consciousness and peripheral neuropathy. Cutaneous features may manifest as telangiectasias, diffuse erythematous streaks, purpuric macules and nodules. The cutaneous variant of the western variant class is a unique subtype which is less aggressive than all other forms of IVLBCL, most commonly affecting pre-menopausal females.

The Asian or hemophagocytic variant, like its counterpart, has a title reminiscent of its origin and is characterized by anemia (66%), thrombocytopenia (58%), hemophagocytosis (61%), bone marrow involvement (75%), respiratory symptoms (34%), B-symptoms (fever, night-sweats; 76%), hypoaolbminaemia (<30 g/L; 61%) and hepatosplenomegaly. In contrast to the Western variant, neurological symptoms (27%) and cutaneous lesions (15%) are rare and, when present, suggest an alternative diagnosis. High lactate dehydrogenase (LDH; 98%) and disseminated intravascular coagulation (DIC; 25%) are common features. Most Asian variant IVLBCL cases have been reported in Southwestern Japan. A few case reports have described the hemophagocytic variant within the Western hemisphere. However, the majority of these have involved either immigrants from eastern countries or a known family history of Asian descent. Our case uniquely describes an African-American within the western hemisphere, presenting with the Asian variant. Theories regarding the source of this the observed geographical difference remain disputed. More recent conjectures have included potential ethnic differences involved in inflammatory marker production such as sIL2R which appears markedly increased in Asian variant patients, in comparison to western variants. Other theories speculate towards an environmental component given that the majority of Asian variant cases have been documented in Southwestern Japan where human T-cell lymphotropic virus type-1 (HTLV-1) is prominent. Helminthic infectious may also represent an environmental trigger. In contrast to other hemophagocytic-associated lymphomas, Epstein-Barr virus (EBV) has been reported in only a few IVLBCL cases and is not thought be causative.

The genetic alterations in IVLBCL remain under investigation. Aberrations in chromosomes 1, 6, 18, 11 and 13 have all been postulated as sources. However, in a retrospective analysis of cytogenetic abnormalities, Shimada et al. identified that only 57% of 84 patients displayed cytogenetic abnormalities. Determination of the progenitor cell lines remains an area of intense investigation. Most cells express CD19, CD20, and CD79a, consistent with B-cell origin. In addition to B cells, both intravascular T cell and natural killer (NK) cell lines have been identified and should not be considered a variant of IVLBCL. It is plausible that Asian variant IVLBCL represents a unique variant of the germinal center B cell-like (GCB) form of CD5+ Diffuse Large B Cell Lymphoma (DLBCL). Accordingly, CD5+ lines may be indicative of the western variant.

The paucity of extravascular migration remains IVLBCL's most perplexing feature. Defective interactions between luminal walls and lymphoma cells may play a role. In healthy individuals, lymphocytes bind to high endothelial venules (HEV) on vessel walls via the lymphocyte homing receptor, thereby allowing transverse movement across the walls into peripheral regions. Western variant IVLBCL, in particular, appears to congregate in regions with low HEV, such as the brain and skin. HEV deficiency within vessel lumens may thus prevent extravasation into the periphery. Other possibilities include deficien-

---

**Figure 1.** Chest computed tomography: Admission CT displaying diffuse hazy opacities in both lung fields with occasional nodular formation.

**Figure 2.** Chest computed tomography: Day 3 CT displaying interval increase in bilateral nodular opacities, air bronchograms and pulmonary edema.

**Figure 3.** Capillary wall congestion with large atypical lymphocytes and diffuse hemorrhage. Hematoxylin and eosin stain, intermediate magnification.

**Figure 4.** Lymphocytes displaying vesicular nuclei, prominent nucleoli and frequent mitotic figures. Coarse nuclear chromatin and indented nuclei noted as well. Hematoxylin and eosin stain, intermediate magnification.
cies in essential transvascular migration molecules such as CD29 (β1-Integrin), CD54 (intracellular adhesion molecule 1), and CD18 (Integrin β2) superficially expressed by lymphoma cells. In the Asian variant, the mechanism of hemophagocytosis remains poorly understood, but may be influenced by macrophage colony stimulating factor and IL-6. It is possible that hemophagocytosis is linked to cellular extravasation as studies have shown that the presence of hemophagocytosis correlates with disease dissemination (along with B-symptoms and elevated levels of soluble IL-2 receptor). Notably, although the majority of IVLBCL cases involve small vessels, at least seven case reports have identified IVLBCL in large vessels. The mechanism of this is unknown.

As stated previously, IVLBCL may present with wide clinical variability. Characteristic physical examination findings associated with lymphoma, such as lymphadenopathy or tumor burden, are often absent thus requiring greater reliance on laboratory data. Suspicion should be raised in patients describing headaches, skin abnormalities, hepatosplenomegaly, or constitutional complaints. Initial laboratory tests should include a complete blood count, serum LDH, β-2 microglobulin, monoclonal serum protein, a complete hepatic and renal panel and thyroid function studies. Cytogenetic studies should also be considered. The gold standard of diagnosis remains organ biopsy. Diffuse spread of the disease allows for physician discretion in determining the biopsy site. For Asian IVLBCL, bone marrow (BM) biopsy offers the most reliable results as intrasinusoidal tumor involvement is frequently encountered (up to 96%). Serial BM biopsies have been shown to enhance diagnostic accuracy. Despite infrequent cutaneous features, Asian-variant IVLBCL is commonly isolated from skin biopsies and if positive, may prove a simple and useful diagnostic procedure. Transbronchial biopsy may be performed if pulmonary symptoms are present. Hepatic and splenic biopsies are useful in the setting of hepatosplenomegaly and show sinusoidal involvement in up to 89% of patients. Tumor cells are large with scant basophilic or amphophilic cytoplasm and moderately dispersed chromatin. Frequent mitotic figures and prominent vesicular nucleoli are common. Cells are rarely detected in peripheral blood. Sinusoidal distribution often occurs within the bone marrow, liver and spleen. As mentioned, erythrocyte-hemagocytic cells are detected in the vast majority of BM biopsies. However, in the appropriate clinical context, the presence of classic findings including thrombocytopenia, fever and hepatosplenomegaly may be considered diagnostic even in the absence of hemophagocytosis. Computed tomography (CT) scans are rarely diagnostic. However, reports regarding the use of 18-Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) have been promising with characteristic uptake in the bone marrow and involved organs. The overall prognosis for most IVLBCL cases remains poor. Historically, most patients have been diagnosed with stage IV disease, or post-mortem. Post-mortem diagnosis appears less common in Asian variants (36%) versus the Western variants (64%). Prognostic comparisons between the Western and Asian variants are similar, as are responses to treatment. The rarity of IVLBCL has made randomized controlled trial assessment difficult. Historically, combination chemotherapy, typically CHOP, has been utilized with dismal results. However, the addition of Rituximab, a monoclonal antibody to CD-20, has led to substantial improvements in recovery, nearly doubling survival length. European studies have determined an 81% survival rate at 3 years with combined immunochemotherapy, versus just 33% in the absence of rituximab. To date, no studies have evaluated the addition of Rituximab specifically in the Asian variant IVLBCL. Autologous stem cell support (ASCT) has been evaluated in a number of small studies and shown efficacy, primarily in individuals under going their first remission. However, the advanced age of most patients excludes them from this option. Allogenic peripheral blood stem cell transplant has been utilized with variable results in the setting of failed chemotherapy. With treatment, Asian variant IVLBCL survival times range 12.5 months to 22.5 months. Cases exclusive to the skin appear to have a better response rate (3-year survival 50%). Median survival with anthracycline therapy is estimated to be 13 months. Etoposide has been effective in the setting of hemophagocytic syndrome.

Conclusions

Despite more than 50 years of research, IVLBCL remains a highly elusive malignancy typified by limited treatment options and a guarded prognosis. We describe the first recorded occurrence of Asian variant IVLBCL in an African-American within the western hemisphere. This case is of particular interest as descriptions of the Asian variant IVLBCL in non-Asian populations is limited. No obvious mechanism has yet surfaced explaining this unique phenomenon. However, environmental factors characteristic to certain topographies may play a lesser role than once previously considered. Alternatively, African and Asian races may share particular genomic sequences predisposing them to the Asian variant. Regardless of the cause, it remains imperative that continued research be promoted to better understand this unique malignancy.

References

1. Pfleger VL, T.J. Zur Kenntnis der systemisierten Endotheliomatose der cuta nen Blutgefaße (Reticuloendothelose)? Hautarzt 1959;10.
2. Harris NL, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haemapoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting. Histopathology 2007;36:69-86.
3. Shimada K, Matsue K, Yamamoto K, et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 2008;26:3189-95.
ralized telangiectasia: a manifestation of intravascular B-cell lymphoma. Dermatology 2008;217:318-20.
5. Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVL-BCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007;109:478-85.
6. Shimada K, Kinoshita T, Naoe T, Nakamura S. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 2009;10:895-902.
7. Tsukadaira A, Okubo Y, Ogasawara H, et al. Chromosomal aberrations in intravascular lymphomatosis. Am J Clin Oncol 2002;25:178-81.
8. Rashid R, Johnson RJ, Morris S, et al. Intravascular large B-cell lymphoma associated with a near-tetraploid karyotype, rearrangement of BCL6, and a t(11;14) (q13;q32). Cancer Genet Cytogenet 2006;171:101-4.
9. Murase T, Nakamura S, Kawachi K, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol 2000;111:826-34.
10. Hamaguchi H, Inokuchi K, Nara N, et al. Alterations in the colorectal carcinoma gene and protein in a novel human myeloid leukemia cell line with trisomy 18 established from overt leukemia after myelodysplastic syndrome. Int J Hematol 1998;67:153-64.
11. Shimazaki C, Inaba T, Shimura K, et al. B-cell lymphoma associated with haemophagocytic syndrome: a clinical, immunological and cytogenetic study. Br J Haematol 1999;104:672-9.
12. Cerroni L, Massone C, Kutzner H, et al. Intravascular large T-cell or NK-cell lymphoma: a rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein-Barr virus infection. Am J Surg Pathol 2008;32:891-8.
13. Kanda M, Suzumiya J, Ohshima K, et al. Analysis of the immunoglobulin heavy chain gene variable region of intravascular large B-cell lymphoma. Virchows Arch 2001;439:540-6.
14. Ferry JA, Harris NL, Picker LJ, et al. Intravascular lymphomatosis (malignant angioendotheliomatosis). A B-cell neoplasm expressing surface homing receptors. Mod Pathol 1988;1:444-52.
15. Ponzoni M, Arrigoni G, Gould VE, et al. Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol 2000;31:220-6.
16. Jalkanen S, Aho R, Kallajoki M, et al. Lymphocyte homing receptors and adhesion molecules in intravascular malignant lymphomatosis. Int J Cancer 1989;44:777-82.
17. Yao X, Saad A, Chitambar CR. Intravascular large B-cell lymphoma, an exclusively small vessel disease? A case report and review of literature. Leuk Res 2010;34:e275-7.
18. Narimatsu H, Morishita Y, Saito S. Usefulness of bone marrow aspiration for definite diagnosis of Asian variant of intravascular lymphoma: four autopsied cases. Leuk Lymphoma 2004;45:1611-6.
19. Miura Y, Tsudo M. Fluorodeoxyglucose-PET/CT for diagnosis of intravascular large B-cell lymphoma. Mayo Clin Proc 2010;85:e56-7.
20. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood 2007;110:3507-16.
21. Shimizu I, Ichikawa N, Yoshimoto M, et al. Asian variant of intravascular lymphoma: aspects of diagnosis and the role of rituximab. Intern Med 2007;46:1381-6.
22. Ferreri A, Dognini G, Gobbi S. Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma? J Clin Oncol. 2008;26:5134-6.
23. Ferreri A, Campo E, Ambrosetti A. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol 2004;15:1215-21.
24. Adam DN, Beleznay KM, Randhawa RS, et al. Review of intravascular lymphoma with a report of treatment with allogeneic peripheral blood stem cell transplant. Cutis 2008;82:267-72.
25. Murase T, Tomita Y, Nakamura S. [Clinicopathologic features of intravascular large B-cell lymphoma in Japan: review of the special reference to the Asian variant]. Rinsho Ketsueki 2002;43:5-11. [Article in Japan].
26. Feldmann R, Schierl M, Sittenthaler M, et al. Intravascular large B-cell lymphoma of the skin: typical clinical manifestations and a favourable response to rituximab-containing therapy. Dermatology 2009;219:344-6.
27. Kawa K, Sakata A, Takeshita Y, Inoue M. [Diagnosis and treatment of hemophagocytic syndrome]. Rinsho Ketsueki 2005;46:418-23. [Article in Japan]